These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24929963)

  • 1. Prognostic value of 3'-deoxy-3'-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas.
    Zhao F; Cui Y; Li M; Fu Z; Chen Z; Kong L; Yang G; Yu J
    Nucl Med Biol; 2014 Sep; 41(8):710-5. PubMed ID: 24929963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3'-Deoxy-3'-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients.
    Idema AJ; Hoffmann AL; Boogaarts HD; Troost EG; Wesseling P; Heerschap A; van der Graaf WT; Grotenhuis JA; Oyen WJ
    J Nucl Med; 2012 Dec; 53(12):1904-10. PubMed ID: 23077112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral heterogeneity of
    Mitamura K; Yamamoto Y; Kudomi N; Maeda Y; Norikane T; Miyake K; Nishiyama Y
    Ann Nucl Med; 2017 Jan; 31(1):46-52. PubMed ID: 27686469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab.
    Schwarzenberg J; Czernin J; Cloughesy TF; Ellingson BM; Pope WB; Geist C; Dahlbom M; Silverman DH; Satyamurthy N; Phelps ME; Chen W
    J Nucl Med; 2012 Jan; 53(1):29-36. PubMed ID: 22159180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 3'-deoxy-3'-[18F]fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma.
    Jeong SY; Lim SM
    Nucl Med Biol; 2012 Oct; 39(7):977-81. PubMed ID: 22483845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can (18)F-FDOPA PET/CT predict survival in patients with suspected recurrent glioma? A prospective study.
    Karunanithi S; Sharma P; Kumar A; Gupta DK; Khangembam BC; Ballal S; Kumar R; Kumar R; Bal C
    Eur J Radiol; 2014 Jan; 83(1):219-25. PubMed ID: 24191944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (18)F-Fluorothymidine PET-CT for resected malignant gliomas before radiotherapy: tumor extent according to proliferative activity compared with MRI.
    Zhao F; Li M; Wang Z; Fu Z; Cui Y; Chen Z; Yu J
    PLoS One; 2015; 10(3):e0118769. PubMed ID: 25738617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of post-treatment metabolic tumor volume from
    Jung TY; Min JJ; Bom HS; Jung S; Kim IY; Lim SH; Kim DY; Kwon SY
    Neurosurg Rev; 2017 Apr; 40(2):223-229. PubMed ID: 27282449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.
    Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH
    Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Guglielmo P; Quartuccio N; Rossetti V; Celli M; Alongi P; Boero M; Arnone G; Baldari S; Matteucci F; Laudicella R
    Curr Med Imaging; 2022; 18(4):363-371. PubMed ID: 34533446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
    Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
    J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
    Chen W; Delaloye S; Silverman DH; Geist C; Czernin J; Sayre J; Satyamurthy N; Pope W; Lai A; Phelps ME; Cloughesy T
    J Clin Oncol; 2007 Oct; 25(30):4714-21. PubMed ID: 17947718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma.
    Enslow MS; Zollinger LV; Morton KA; Butterfield RI; Kadrmas DJ; Christian PE; Boucher KM; Heilbrun ME; Jensen RL; Hoffman JM
    Clin Nucl Med; 2012 Sep; 37(9):854-61. PubMed ID: 22889774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.
    Schöder H; Zelenetz AD; Hamlin P; Gavane S; Horwitz S; Matasar M; Moskowitz A; Noy A; Palomba L; Portlock C; Straus D; Grewal R; Migliacci JC; Larson SM; Moskowitz CH
    J Nucl Med; 2016 May; 57(5):728-34. PubMed ID: 26719374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ¹⁸F-FLT    and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors.
    Wardak M; Schiepers C; Cloughesy TF; Dahlbom M; Phelps ME; Huang SC
    Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1199-209. PubMed ID: 24604590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma.
    Hatakeyama T; Kawai N; Nishiyama Y; Yamamoto Y; Sasakawa Y; Ichikawa T; Tamiya T
    Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2009-17. PubMed ID: 18542957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
    Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
    J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
    Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
    Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeatability of
    Lodge MA; Holdhoff M; Leal JP; Bag AK; Nabors LB; Mintz A; Lesser GJ; Mankoff DA; Desai AS; Mountz JM; Lieberman FS; Fisher JD; Desideri S; Ye X; Grossman SA; Schiff D; Wahl RL
    J Nucl Med; 2017 Mar; 58(3):393-398. PubMed ID: 27688473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.